RiteMED Cefuroxime

Tab: Treatment of susceptible infections including upper & lower resp tract, uncomplicated skin & skin structure infections, uncomplicated UTI, uncomplicated gonorrhea & early Lyme disease. Inj: Treatment of infections including resp tract infections, UTI, skin & soft tissue infections, septicemia, meningitis, gonorrhea & bone & joint infections.

Tab Adult & adolescent ≥13 yr Acute sinusitis, tonsillopharyngitis & bacterial exacerbations of chronic bronchitis; uncomplicated skin & skin structure infections 250-500 mg 12 hrly for 10 days. Acute otitis media 500 mg 12 hrly for 10 days. Secondary bacterial infections of acute bronchitis 250-500 mg 12 hrly for 5-10 days. Uncomplicated UTI including pyelonephritis 250-500 mg 12 hrly for 7-10 days. Uncomplicated gonorrhea 1,000 mg as a single dose. Early Lyme disease 500 mg 12 hrly for 20 days. Inj Deep IM inj, slow IV inj over 3-5 min or by IV infusion. Adult 750 mg by IM or IV inj every 8 hr. Severe infection 1.5 mg IV every 6-8 hr. Pneumonia 1.5 mg IM or IV inj bid for 48-72 hr followed by oral cefuroxime for 7-10 days. Acute exacerbation of chronic bronchitis 750 mg IM or IV inj bid followed by oral cefuroxime for 5-10 days. Meningitis 3 g IV every 8 hr. Gonorrhea 1.5 g IM single dose, divided between 2 different inj sites. Surgical infection prophylaxis 1.5 g IV pre-op, supplemented by 750 mg IM every 8 hr for up to 24-48 hr depending upon the procedure. Infant & childn 30-60 mg/kg daily, increase to 100 mg/kg daily if necessary, given in 3 or 4 divided doses. Meningitis 200-400 mg/kg daily IV in 3-4 divided doses, decreased to 100 mg/kg daily after 3 days or when there is clinical improvement. Neonates Similar dose w/ infant & childn, but in 2 or 3 divided doses. Meningitis 100 mg/kg IV daily, decreased to 50 mg/kg daily when indicated. Adult w/ marked renal impairment (CrCl 10-20 mL/min) 750 mg bid; <10 mL/min 750 mg once daily. Patients on hemodialysis 750 mg by IV or IM at the end of each dialysis.

Should be taken with food.

Hypersensitivity.

Hypersensitivity. Elderly. Tab: Consider diagnosis of C. difficile-associated diarrhea (CDAD) in patients who develop diarrhea. Discontinue use if seizure develops. History of GI disease particularly colitis. Monitor prothrombin time. Transient Jarisch-Herxheimer reaction. Porphyria; renal & hepatic impairment. Overgrowth of nonsusceptible organism (prolonged or repeated use). May impair ability to drive or operate machinery. Pregnancy & lactation. Inj: Monitor renal function in patients receiving high dose cephalosporins; pre-existing renal impairment.

Tab: Dermatologic/hypersensitivity reactions, GI, hematologic, nervous system, musculoskeletal, genitourinary, hepatic, resp & CV effects; Jarisch-Herxheimer reaction, mild to severe hearing loss, increased or decreased serum glucose conc, lockjaw-type reactions & viral illness. Inj: GI disturbance including diarrhea, nausea, vomiting; SJS & TEN; moderate hearing loss.

Tab: Increased conc & reduced tubular secretion w/ probenecid. Increased risk of nephrotoxicity w/ aminoglycosides. Concomitant use of potent diuretics including furosemide & ethacrynic acid may increase the risk of renal toxicity. Decreased bioavailability w/ oral antacids. May reduce estrogen absorption & efficacy of combined OCs. Inj: Reduced renal clearance w/ probenecid.

Cephalosporins

J01DC02 - cefuroxime ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.

Rx